Reviewer's report

Title: Impact of Efalizumab on Patient-Reported Outcomes in High-Need Psoriasis Patients: Results of the International, Randomized, Placebo-Controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) Trial [IMP24011]

Version: 2 Date: 7 December 2005

Reviewer: Dan J Pearce

Reviewer's report:

General

Well written and the authors' responses adequately address my comments. The revisions are appropriate. Thanks.

-------------------------------------------------------------------------------------------------------------------------------------

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

-------------------------------------------------------------------------------------------------------------------------------------

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

-------------------------------------------------------------------------------------------------------------------------------------

Discretionary Revisions (which the author can choose to ignore)

What next?: Accept without revision

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:

speaker's bureau for Biogen Idec
Indirect research support from Genetech, Abbott Labs, Connetics, Amgen.